They have a somewhat worse off patient population then leronlimab. But an easier primary endpoint.

Their drug downregulates NF-kB which is an important immune regulator and also one of the many that leronlimab regulates. What has me puzzled is they ended enrollment in late September with claimed superior results and yet no approval as of now.